Bionoid Pharma Inc
AI Maverick Intel, Inc., an AI company, focuses on acquiring and enhancing businesses through its proprietary AI Maverick platform. Its technology streamlines the customer acquisition process by automating two way communication and data-driven engagement with its clients ideal audience segments across healthcare, biotech, and other sectors. The company was formerly known as Bionoid Pharma Inc. an… Read more
Bionoid Pharma Inc (BINP) - Net Assets
Latest net assets as of June 2025: $3.93 Million USD
Based on the latest financial reports, Bionoid Pharma Inc (BINP) has net assets worth $3.93 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.08 Million) and total liabilities ($150.31K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.93 Million |
| % of Total Assets | 96.31% |
| Annual Growth Rate | N/A |
| 5-Year Change | -120.25% |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Bionoid Pharma Inc - Net Assets Trend (2006–2023)
This chart illustrates how Bionoid Pharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bionoid Pharma Inc (2006–2023)
The table below shows the annual net assets of Bionoid Pharma Inc from 2006 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-84.04K | -10.24% |
| 2022-12-31 | $-76.23K | +1.90% |
| 2021-12-31 | $-77.71K | -89.99% |
| 2020-12-31 | $-40.90K | -109.86% |
| 2019-12-31 | $414.98K | +36388.29% |
| 2013-12-31 | $-1.14K | +99.88% |
| 2011-12-31 | $-947.66K | -8.81% |
| 2010-12-31 | $-870.90K | +38.64% |
| 2009-12-31 | $-1.42 Million | +6.72% |
| 2008-12-31 | $-1.52 Million | -66.44% |
| 2007-12-31 | $-914.26K | -512.00% |
| 2006-12-31 | $-149.39K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bionoid Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1468667000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.40K | % |
| Other Components | $19.09 Million | % |
| Total Equity | $-84.03K | 100.00% |
Bionoid Pharma Inc Competitors by Market Cap
The table below lists competitors of Bionoid Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Werth Holz SA
WAR:WHH
|
$476.62 |
|
Santeon Group Inc
PINK:SANT
|
$476.80 |
|
IDT INTL
MU:IIN
|
$477.14 |
|
Xtreme One Entertainment, Inc.
PINK:XONI
|
$477.20 |
|
Jarvis Securities
LSE:JIM
|
$476.22 |
|
Reebonz Holding Ltd
PINK:RBZHF
|
$475.40 |
|
ABC COMMUNICATIONS
BE:ABM
|
$474.74 |
|
Republic Glass Holdings Corp
PSE:REG
|
$474.65 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bionoid Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -76,230 to -84,035, a change of -7,805.
- Net income of 11,725 contributed positively to equity growth.
- Other comprehensive income decreased equity by 20,642,845.
- Other factors increased equity by 20,623,315.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $11.72K | +13.95% |
| Other Comprehensive Income | $-20.64 Million | -24564.58% |
| Other Changes | $20.62 Million | +24541.34% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Bionoid Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $-0.01 | $0.05 | x |
| 2007-12-31 | $-0.06 | $0.05 | x |
| 2008-12-31 | $-0.09 | $0.05 | x |
| 2009-12-31 | $-0.07 | $0.05 | x |
| 2010-12-31 | $-0.03 | $0.05 | x |
| 2011-12-31 | $-61.79 | $0.05 | x |
| 2013-12-31 | $-32.61 | $0.05 | x |
| 2019-12-31 | $10.86 | $0.05 | x |
| 2020-12-31 | $-1.07 | $0.05 | x |
| 2021-12-31 | $0.00 | $0.05 | x |
| 2022-12-31 | $0.00 | $0.05 | x |
| 2023-12-31 | $0.00 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bionoid Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.26%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.55%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.06 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.17 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.44 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.27 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.82 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.05 Million |
| 2013 | 0.00% | -1759.10% | 0.67x | 0.00x | $-1.51K |
| 2019 | 6.54% | 48.33% | 0.11x | 1.28x | $-14.35K |
| 2020 | 0.00% | -1486.72% | 0.25x | 0.00x | $-451.69K |
| 2021 | 0.00% | -132.20% | 1.21x | 0.00x | $-127.23K |
| 2022 | 0.00% | 4.10% | 0.43x | 0.00x | $9.10K |
| 2023 | 0.00% | 31.26% | 0.53x | 0.00x | $20.13K |
Industry Comparison
This section compares Bionoid Pharma Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bionoid Pharma Inc (BINP) | $3.93 Million | 0.00% | 0.04x | $476.50 |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |